1. Home
  2. QNTM
  3. QNTM News

Latest QUANTUM BIOPHARMA LTD (QNTM) News on January 19, 2025

QNTM

ACCESS Newswire

2 days ago

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

QNTM

ACCESS Newswire

5 days ago

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

QNTM

ACCESSWIRE

12 days ago

Quantum Biopharma Ltd. Approved to Dual List on Upstream

QNTM

ACCESSWIRE

a month ago

Quantum Biopharma Announces Closing of Second Tranche

QNTM

ACCESSWIRE

a month ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

QNTM

ACCESSWIRE

a month ago

Quantum Biopharma Announces Closing of First Tranche

QNTM

ACCESSWIRE

a month ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

QNTM

ACCESSWIRE

a month ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million

QNTM

ACCESSWIRE

2 months ago

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
QNTM

ACCESSWIRE

3 months ago

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

QNTM

ACCESSWIRE

3 months ago

Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
QNTM

Newsfile

3 months ago

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
QNTM

ACCESSWIRE

3 months ago

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
QNTM

Newsfile

3 months ago

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America

Quantum Biopharma Provides Corporate Update
QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Provides Corporate Update

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
QNTM

ACCESSWIRE

4 months ago

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US

Quantum BioPharma Closes Private Placement Offering
QNTM

Newsfile

4 months ago

Quantum BioPharma Closes Private Placement Offering

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

QNTM

ACCESSWIRE

4 months ago

Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
QNTM

ACCESSWIRE

5 months ago

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80

QNTM

ACCESSWIRE

5 months ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what’s NEXT"

QNTM

ACCESSWIRE

5 months ago

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

QNTM

Newsfile

5 months ago

FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"

Share on Social Networks: